These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37560283)

  • 41. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
    Diemberger I; Fumagalli S; Mazzone AM; Bakhai A; Reimitz PE; Pecen L; Manu MC; Gordillo de Souza JA; Kirchhof P; De Caterina R
    Europace; 2022 Oct; 24(9):1404-1411. PubMed ID: 35512229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban].
    Riva L; Diemberger I; Di Pasquale G; Attena E; Sangiuolo R; De Caterina R
    G Ital Cardiol (Rome); 2020 Feb; 21(2):141-151. PubMed ID: 32051638
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).
    Lip GYH; Merino JL; Dan GA; Themistoclakis S; Ellenbogen KA; De Caterina R; Goudev A; Jin J; Melino M; Winters SM; Goette A
    Am J Cardiol; 2018 Jan; 121(2):193-198. PubMed ID: 29169605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study.
    Russo V; Attena E; Rago A; Melillo E; Di Micco P; Papa AA; Napolitano G; D'Onofrio A; Golino P; Nigro G
    J Clin Med; 2020 May; 9(6):. PubMed ID: 32471222
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Magnuson EA; Vilain K; Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ;
    Am Heart J; 2015 Dec; 170(6):1140-50. PubMed ID: 26678636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
    Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD;
    N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.
    Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
    Sci Rep; 2019 Apr; 9(1):6690. PubMed ID: 31040359
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study.
    Colonna P; von Heymann C; Santamaria A; Saxena M; Vanassche T; Wolpert D; Laeis P; Wilkins R; Chen C; Unverdorben M
    Clin Cardiol; 2020 Jul; 43(7):769-780. PubMed ID: 32406557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
    Agnelli G; Hoffmann U; Hainaut P; Gaine S; Ay C; Coppens M; Schindewolf M; Jimenez D; Brüggenjürgen B; Levy P; Laeis P; Fronk EM; Zierhut W; Malzer T; Manu MC; Reimitz PE; Bramlage P; Cohen AT;
    Thromb Res; 2020 Dec; 196():297-304. PubMed ID: 32950897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
    Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
    SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
    Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
    Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort.
    Nielsen PB; Larsen TB; Skjøth F; Søgaard M; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):31-39. PubMed ID: 31774504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
    Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study.
    Unverdorben M; von Heymann C; Santamaria A; Saxena M; Vanassche T; Jin J; Laeis P; Wilkins R; Chen C; Colonna P
    BMC Cardiovasc Disord; 2020 Dec; 20(1):504. PubMed ID: 33256590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
    J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
    Nielsen PB; Søgaard M; Jensen M; Ording AG; Lip GY
    Int J Stroke; 2022 Jun; 17(5):536-544. PubMed ID: 34142600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.